Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy aims to boost brain repair after stroke

NCT ID NCT05935787

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a drug called Cytoflavin to standard physical rehab helps stroke survivors recover better. Cytoflavin is an antioxidant that may protect brain cells and improve learning of new skills. The trial involved 240 adults aged 40-80 who had a stroke 2 weeks to 3 months earlier. Half got Cytoflavin plus rehab, the other half got placebo plus rehab, and researchers measured changes in daily living skills.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

240 people

The number who actually took part.

Started

Jun 2023

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed Patient informed consent form 2. Men and women aged 40 to 80, inclusive. 3. Ischemic stroke in the carotid area, or hemorrhagic stroke in the cerebral hemispheres, occurred in the previous 14-90 days before screening. 4. Acute neuroimaging data (CT and/or MRI) do not contradict the clinical and topical diagnosis of stroke. 5. The presence of a measurable neurological deficit in the motor or sensory area. 6. Availability of rehabilitation potential, which is assessed by the specialists of the multidisciplinary team 7. Modified Rankin score 3-4. 8. The possibility to visit outpatient rehabilitation at the research center. 9. Ability to understand and comply with protocol requirements. 10. For women: consent to use reliable methods of contraception or absent reproductive potential. 11. For men: consent to the use of adequate methods of contraception, or complete abstinence from sexual activity for the period of the study, or absent reproductive potential. Exclusion Criteria: 1. Known hypersensitivity to any component of the study drug 2. Severe visual and hearing impairments that prevent the implementation of study procedures. 3. Severe spasticity (scored 3-4 by Ashworth scale). 4. Impaired swallowing, which does not allow taking drugs orally. 5. Communication deficit that does not allow the patient to fulfill the conditions of the study protocol (including total aphasia). 6. The presence of contraindications to complex rehabilitation in a hospital (lack of rehabilitation potential, somatic diseases that prevent a complex of rehabilitation measures). 7. Aneurysmal subarachnoid hemorrhage. 8. Previous (before the actual ictus) stroke with residual neurological deficit. 9. Disability is primarily not attributed to the last stroke 10. Severe renal failure 11. Severe liver failure 12. End stage of other chronic incurable diseases. 13. Decompensated diabetes mellitus. 14. History of cancer, mental illness, HIV infection, syphilis, tuberculosis, alcohol, drug or drug addiction. 15. Established diagnosis of a mental or neurodegenerative disease 16. Constant use of psychotropic drugs (neuroleptics, tranquilizers, antidepressants) or nootropic drugs in the previous 3 months before the patient was included in the study, except for stroke treatment in acute hospital. 17. Alcohol or drug addiction 19\. Pregnancy, lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemorrhagic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City General Hospital №2

    Saint Petersburg, Russia

  • City Hospital №40 of the Kurortny District

    Saint Petersburg, Russia

  • Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine

    Saint Petersburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.